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Neuropilin 1 is an entry factor that promotes EBV
infection of nasopharyngeal epithelial cells
Hong-Bo Wang1,*, Hua Zhang1,*, Jing-Ping Zhang1, Yan Li1, Bo Zhao2, Guo-Kai Feng1, Yong Du1, Dan Xiong1,
Qian Zhong1, Wan-Li Liu1, Huamao Du3, Man-Zhi Li1, Wen-Lin Huang1, Sai Wah Tsao4, Lindsey Hutt-Fletcher5,
Yi-Xin Zeng1, Elliott Kieff2 & Mu-Sheng Zeng1
Epstein–Barr virus (EBV) is implicated as an aetiological factor in B lymphomas and
nasopharyngeal carcinoma. The mechanisms of cell-free EBV infection of nasopharyngeal
epithelial cells remain elusive. EBV glycoprotein B (gB) is the critical fusion protein for
infection of both B and epithelial cells, and determines EBV susceptibility of non-B cells. Here
we show that neuropilin 1 (NRP1) directly interacts with EBV gB23–431. Either knockdown of
NRP1 or pretreatment of EBV with soluble NRP1 suppresses EBV infection. Upregulation of
NRP1 by overexpression or EGF treatment enhances EBV infection. However, NRP2, the
homologue of NRP1, impairs EBV infection. EBV enters nasopharyngeal epithelial cells
through NRP1-facilitated internalization and fusion, and through macropinocytosis and
lipid raft-dependent endocytosis. NRP1 partially mediates EBV-activated EGFR/RAS/ERK
signalling, and NRP1-dependent receptor tyrosine kinase (RTK) signalling promotes EBV
infection. Taken together, NRP1 is identiﬁed as an EBVentry factor that cooperatively activates
RTK signalling, which subsequently promotes EBV infection in nasopharyngeal epithelial cells.
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E
pstein–Barr virus (EBV) is a ubiquitous human herpesvirus
4 (HHV4) that establishes latent infections in 490% of the
adult population worldwide1,2. EBV is implicated as an
aetiological factor in multiple malignancies of either lymphoid
or epithelial origin, including Burkitt lymphoma, Hodgkin’s
lymphoma, gastric carcinoma and nasopharyngeal carcinoma
(NPC), suggesting its primary tropism for these cells2,3. The
mechanism involved in EBV infection of B cells has been well
elucidated, while the mechanisms of EBV infection of epithelial
cells remain elusive, mainly due to the lack of representative cell
model that are highly susceptible to cell-free EBV infection4–6.
EBV infection of B cells consists of at least two distinct
mechanistic steps7. EBV attaches to the targeted cells through the
interaction of EBV glycoprotein gp350/220 with CD21 (the B cell
complement receptor, CR2) or CD35 (refs 8,9). Subsequently,
EBV fuses and penetrates into B cells, triggered by the interaction
of gp42 (an additional EBV glycoprotein) with HLA class II, in
the presence of EBV gB and gHgL (the core fusion machinery)10.
However, the binding receptors CD21 and CD35, and the fusion
receptor HLA class II, are expressed at low or undetectable levels
in epithelial cells11,12. Therefore, EBV gp42 and gp350 were not
essential in EBV infection of epithelial cells, suggesting different
mechanisms contributing to EBV infection of epithelial cells12.
EBV gB is the most highly conserved glycoprotein required for
membrane fusion in herpesviruses, but its cellular mediator
involved in EBV fusion has not been identiﬁed so far13. EBV
strains with higher expression of gB exhibit an increased capacity
to infect cells that are normally refractory to EBV infection14.
EBV gB contains a consensus furin cleavage site15,16. After
cleavage by furin, EBV gB exhibited as a N-terminal peptide with
78 kDa, and a C-terminal peptide with 58 kDa. Both full-length
and furin-cleaved gB are moderately abundant potential fusogens
in mature EBV envelopes16. Deletion of the consensus furin
cleavage site of gB, which is speculated to be a potential cryptic
CendR motif, results in the suppression of cell-cell fusion,
indicating the importance of this site to EBV infection15. Peptides
that expose the CendR motif with the consensus sequence
R/K/XXR/K at the C-terminus bind to Neuropilin 1 (NRP1) and
are internalized into the cell17,18.
NRP1, as a co-receptor for class III semaphorins and multiple
growth factors, such as EGF, VEGF, PDGF, HGF, TGF-b and
FGF, cooperatively enhances the activity of the receptor tyrosine
kinases (RTKs)19. In addition, NRP1 mediates the penetration of
iRGD conjugated nanoparticles into tissue and cells through
functioning as a receptor for CendR motif, the proteolytic
cleavage products of iRGD after binding to integrins17,20.
Multiple viruses possess CendR motifs within their capsid
proteins and may undergo proteolytic cleavage to expose the
CendR motif to be infective18. Human T-cell lymphotropic virus
type 1 (HTLV-1) is one of such virus that bind to and internalize
into immune cells via the interaction with NRP1 and its surface
subunit (SU) containing a CendR motif (KPXR)21,22.
Together, these observations led us to deduce that NRP1 might
serve as an unidentiﬁed entry factor or a cellular mediator for gB
during EBV infection. Here, we demonstrate that NRP1 interacts
with EBV gB and promotes EBV infection of epithelial cells by
coordinating the RTK signalling pathway and macropinocytic
events.
Results
EBV gB directly interacts with NRP1. Multiple viruses,
including EBV, possess CendR motifs18, a structure that
speciﬁcally mediates NRP1—dependent tissue and cell
penetration. To examine the potential physical interaction of gB
with NRP1, co-immunoprecipitations were performed in
HEK-293FT cells transfected with expression plasmids for both
NRP1 (NRP1-EGFP) and the CendR motif exposed gB23–431
(FLAG-gB). Consistent with the previous reports about the
crystal structure analysis23, gB23–431 mainly presented as the
trimeric form, determined by either western blotting analysis
of the natural form of gB23–431 in DSS cross-linked
gB-overexpressing cells or native–PAGE analysis of the puriﬁed
pulled-down gB (Supplementary Fig. 1). Immuoprecipitation
with either anti-FLAG or anti-EGFP antibody demonstrated the
physical interaction of gB23–431 and NRP1 (Fig. 1a). Furthermore,
this interaction acted in a direct manner, conﬁrmed by an in vitro
binding assay of the commercial soluble NRP1 (sNRP1) and
FLAG-gB23–431 isolated from the supernatants of HEK-293FT
cells (Fig. 1b).
To investigate whether the CendR motif (gB428-431) mediates
the interaction between NRP1 and gB, the interaction between
NRP1 and gB mutants with various deletion was determined by
an in vitro binding assay. The CendR motif—deletion mutant
gB23–427 still retained binding afﬁnity to NRP1, although the
binding was substantially reduced in comparison to that of the
CendR motif—containing gB23–431 (Fig. 1c), indicating that in
addition to the CendR motif another element may also contribute
to the interaction of gB and NRP1. Reimer et al.24 reported
that the insertion of a 5-amino-acid sequence at residue 88 of
gB abolished cell-cell fusion activity. Therefore, gB89–431 and
gB89–427, the mutants with deletion of gB23-88, were further
analysed for their interaction with NRP1. EBV gB89–427, with
deletion of both gB23–88 and gB428–431 (the CendR motif), almost
has no interaction with NRP1 (Fig. 1d). These data suggested that
both gB23–88 and gB428–431 (the CendR motif) might be involved
in the interaction between NRP1 and gB.
NRP1 enhances EBV entry into nasopharyngeal epithelial cells.
Given the physical interaction of NRP1 and gB, we proceeded to
determine whether NRP1 mediated EBV infection of nasophar-
yngeal epithelial cells. EBV is present in the most undifferentiated
NPC tumor cells and is occasionally detected in the pre-invasive
lesions2,25–27. However, nasopharyngeal epithelial cells are
relatively refractory to cell-free EBV infection5,28. We ﬁrst
screened primary nasopharyngeal epithelial cells (NPEC03 and
NPECw), immortalized nasopharyngeal epithelial cells (NP69,
NPEC1-Bmi1 and NPEC2-Bmi1) and nasopharyngeal cancer
cells (SUNE1, SUNE2, 6-10B, CNE1, CNE2 and HNE1) to
identify cell lines with higher infection efﬁciency by using the
recombinant Akata GFP-EBV, which expresses high levels of gB.
The full-length and cleaved forms of gB were found to be present
in the puriﬁed virus (Supplementary Fig. 2). The primary cells
(NPEC03), immortalized cells (NPEC1-Bmi1 and NPEC2-Bmi1)
and NPC cancer cells (HNE1) were relatively sensitive to cell-free
EBV infection, with the infection rate ranging from 10 to 20%.
(Supplementary Fig. 3a). Hence, NPEC1-Bmi1 and HNE1 cells
were used for most of the further infection experiments. The
expressions of CD21 and CD35, which are essential for EBV
infection of B cells8,9, were undetectable in these cells, determined
by real-time PCR (Supplementary Fig. 3b,c). In addition, EBV
infection could not be inhibited by the blocking antibody against
gp350 (Supplementary Fig. 4). These data suggested that EBV
infection of nasopharyngeal epithelial cells was not dependent on
CD21, CD35 and gp350.
To determine whether NRP1 is important for EBV infection,
siRNA and blocking assays were performed. Compared with
siControl-transfected HNE1 cells, siNRP1 transfectants were
relatively resistant to EBV infection with an approximately
twofold decrease. In contrast, knockdown of neuropilin 2
(NRP2), the homologue of NRP1, increased EBV infection by
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about twofold (Fig. 2a,b and Supplementary Fig. 5). Pre-
incubation of EBV with the soluble ectodomain of NRP1
(NRP1ABC) inhibited EBV infection by about 50%, whereas an
anti-NRP2 antibody increased EBV infection by about threefold
(Fig. 2c).
Next, we examined the role of overexpression of NRP1 and
NRP2 on EBV infection. The efﬁciency of EBV infection was
signiﬁcantly enhanced by an increase in NRP1 expression,
whereas overexpression of NRP2 inhibited EBV infection
(Fig. 2d,e and Supplementary Fig. 6). Epidermal growth factor
(EGF) is a known cytokine that induces NRP1 expression in
multiple cancer cells29. To examine the effect of EGF on the
expression of NRP1 and EBV infection, HNE1 cells were
incubated with EGF for 24 h. EGF signiﬁcantly enhanced the
expression of NRP1 in HNE1 cells, but did not change the level of
NRP2 (Fig. 2f). Consistently, the efﬁciency of EBV infection was
signiﬁcantly enhanced by EGF (Fig. 2g, Supplementary Figs 6
and 7). In addition, EGF promotes EBV infection and the
expression of NRP1 in a dose-dependent manner (Supplementary
Fig. 8). Furthermore, knockdown of NRP1 led to a signiﬁcantly
decreased EBV infection in EGF-treated HNE1 and NPEC1-Bmi1
cells maintained in KSF medium supplemented with EGF
(Fig. 2h,i and Supplementary Fig. 9), suggesting that EGF-
induced uptake of EBV at least partially depended on the
induction of NRP1.
NRP1 is a receptor for a number of ligands (for example,
semaphorins, VEGF-A)30,31. To investigate whether the binding
of NRP1 and its ligands would affect EBV infection, HNE1 cells
were incubated with the indicated doses of NRP1 ligands
(SEMA3A, SEMA3F or VEGFA) for 1 h before EBV infection.
SEMA3A, SEMA3F or VEGFA had no effect on EBV infection
(Supplementary Fig. 10); however, whether other ligands for
NRP1 affect EBV infection remains to be further investigated.
NRP1 co-localizes with EBV and binds to EBV-gB. To inves-
tigate whether NRP1 could directly mediate EBV infection, we
examined the localization of EBV and NRP1 in NRP1-over-
expressing HNE1 cells. Confocal microscopy revealed that both
Alexa Fluor 594-labelled EBV and anti-gp350 antibody-stained
EBV co-localized with NRP1-EGFP on the cell membrane
or at vesicular structures (Fig. 3a and Supplementary Fig. 11).
Similarly, the co-localized signals of NRP2 and EBV could also be
detected (Fig. 3b).
The binding of the puriﬁed EBV gB23–431 and GST-NRP1 or
GST-NRP2 was then analysed by ELISA. The apparent afﬁnity
constant for binding of gB and NRP2 was higher than that for gB
and NRP1 (Fig. 3c,d).
As NRP1 and NRP2 played opposite effects on EBV infection,
we therefore evaluated whether NRP2 would affect the binding of
NRP1 to gB. Co-immunoprecipitation indicated that the inter-
action of NRP1 and gB was obviously reduced in the presence of
NRP2 (Fig. 3e).
NRP1 facilitates EBV internalization and fusion. As mentioned
above, EBV entry comprises at least two steps, including binding
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Figure 1 | NRP1 mediates EBV infection through interaction with EBV-gB. (a) NRP1 co-immunoprecipitated with EBV gB. HEK-293FTcells co-transfected
with pEGFP-NRP1 (EGFP-tagged NRP1) and pCEP-FLAG-gB23–431 (FLAG-labelled gB23–431) for 36 h were immunoprecipitated (IP) with an antibody against
FLAG or GFP, followed by immunoblotting (IB) analysis for the complex with the indicated antibody. (b) Puriﬁed EBV-gB23–431 interacted with soluble NRP1
(sNRP1) in vitro. FLAG-gB23–431, puriﬁed from the supernatant of HEK-293FT-pCEP-FLAG-gB23–431 stable cell line, was incubated with the commercial
sNRP1. The protein complex was captured with the anti-FLAG or mIgG (control) and analysed by immunoblotting with anti-NRP1 or anti-FLAG antibodies.
Input is the puriﬁed EBV-gB23–431 and sNRP1. (c,d) gB428–431 (CendR motif) is an important element for gB to interact with NRP1 produced by an in vitro
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products were incubated with the soluble NRP130–636 (sNRP130–636) expressed by an in vitro transcription–translation system. The immune complex was
analysed by immunoblotting (IB) with anti-NRP1 or anti-FLAG antibodies. (e) Schematic summary of NRP1 and gB interactions.
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(attachment) and penetration (fusion)7. We then investigated in
which step NRP1 played a role. Upregulation of NRP1 by either
overexpression or EGF treatment increased EBV internalization
by about 2.5-fold, while knockdown of NRP1 by siRNA caused a
decrease to about 50% of the control. In contrast, overexpression
of NRP2 impaired EBV internalization, while knockdown of
NRP2 enhanced EBV internalization. Both gain- and loss-of-
function experiments revealed that neither NRP1 nor NRP2
exerted any effect on EBV binding (Fig. 4a–c). To determine the
role of NRP1 or NRP2 in the efﬁciency of cell-cell fusion, NRP1-
or NRP2-overexpressing HEK-293FT cells were co-cultured with
EBV glycoproteins (gB and gH/gL)-overexpressing HEK-293FT
cells. Overexpression of NRP1 signiﬁcantly promoted cell-cell
fusion while overexpression of NRP2 had no effect on cell fusion
(Fig. 4d).
Collectively, these data suggested that NRP1 may facilitate EBV
internalization and fusion, but not binding.
EBV enters cells via endocytosis. It has been reported that NRP1
mediates endocytosis via different pathways, depending on its
ligands32. We thus examined the mechanistic basis for EBV
endocytosis. Enveloped viruses penetrate into the cytosol directly
through caveolae-mediated endocytosis (for particles with size of
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Figure 2 | NRP1 enhances EBV infection, while NRP2 suppresses EBV infection. (a,b) Downregulation of NRP1 impaired, whereas knockdown of
NRP2 promoted EBV infection. HNE1 cells were transfected with siRNA duplexes targeting NRP1 or NRP2 for 48 h, followed by NRP expression analysis by
real-time PCR (a) or analysis for the efﬁciency of EBV infection (b); n¼ 3. (c) EBV infection was blocked by soluble NRP1ABC, but enhanced by antibody
against NRP2. For NRP1ABC protein-blocking experiment, HNE1 cells were infected with EBV, which was pre-incubated with puriﬁed NRP1ABC for 1 h. For
antibody against NRP2-blocking experiment, HNE1 cells were pre-incubated with an anti-NRP2 antibody (100mgml 1) or goat IgG (control) at 4 C for 1 h
and then were exposed to EBV at an MOI of 5 103 for 3 h at 4 C. (d,e) Overexpression of NRP1 enhanced EBV infection, while NRP2 suppressed EBV
infection. HNE1 cells were transiently transfected with the expression plasmid for NRP1, NRP2 or the empty vector (pMSCV) for 24 h, followed by analysis
for the expression of NRP1 and NRP2 by western blotting (d) or were exposed to EBV (e). (f,g) EGF upregulated NRP1 expression and enhanced EBV
infection. HNE1 cells cultured with 10 ngml 1 EGF for 24 h were analysed for the expression of NRP1 and NRP2 by western blotting (f) or were exposed to
EBV (g). (h,i) EGF-enhanced EBV infection was partially dependent on NRP1. After transfected with siRNA against NRP1 for 48 h, EGF-treated HNE1 and
NPEC-Bmi1 cells maintained in KSF medium supplemented with EGF were analysed for NRP1 expression by western blotting (h) or were exposed to EBV (i).
For (b), (c), (e), (g) and (i), HNE1 or NPEC1-Bmi1 cells were exposed to EBV at an MOI of 2.5 103 for 2 h at 37 C, unless otherwise indicated. The
percentage of GFP-positive infected cells was analysed by FACS 48 h post infection, with controls (empty vector-transfected cells or vehicle treated-cells)
set to 100%. Data represent three to ﬁve independent experiments. Values in all graphs are means±s.e.m. ***Po0.001; **Po0.01; *Po0.05; Student’s
t-test. For (d), (f) and (h), GAPDH served as an internal control.
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50–80 nm), clathrin-mediated endocytosis (CME, for particles
with size of 85–180 nm) and macropinocytosis (for particles with
size of 0.5–10 mm)33. EBV is an enveloped virus with a diameter
of 120–220 nm. Therefore, EBV infection is unlikely to be
dependent on caveloae-mediated endocytosis. Confocal analysis
showed that both EBV-Alexa ﬂuor 594 and NRP1 co-localized
with SNX5 (marker of macropinocytosis), but not with CLCa
(marker of CME) (Fig. 5a–d), suggesting that NRP1-mediated
EBV internalization may be dependent on macropinocytosis,
but not CME. To further verify this observation, EGF-treated
HNE1 cells and NPEC1-Bmi1 cells were pre-incubated with
the inhibitors of macropinocytosis (5-(N-ethyl-N-isopropyl)-
amiloride, EIPA), lipid raft-dependent endocytosis (Methyl-b-
cyclodextrin, MbCD) and CME (Chlorpromazine, CPZ) at the
indicated concentration for 30min, and then infected with EBV
for 2 h. The cells were then washed with Hanks solution and
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cultured for 48 h. EBV infection was dose-dependently
suppressed by MbCD and EIPA, but not by CPZ in both type
of cells, with preserved cell viability (Fig. 5e–g and Supplementary
Fig. 12). These data demonstrated that EBV entered epithelial
cells via macropinocytosis and lipid raft-dependent endocytosis,
but not clathrin-mediated endocytosis.
EBV activates NRP1-dependent EGFR signalling pathways.
Macropinocytosis and lipid raft-dependent endocytosis can be
induced by RTKs34,35. As a co-receptor of RTKs, NRP1 enhances
the afﬁnity of multiple growth factors, such as EGF, HGF,
VEGF, PIGF and PDGF-BB, to RTKs and thus augments RTKs
signalling36–40. EGFR, the prototypical RTK aberrantly expressed
in NPC41, as well as its critical downstream signalling
components AKT and ERK, was rapidly phosphorylated at
10min post EBV infection, and the phosphorylation increased
and persisted for at least 120min (Fig. 6a). To exclude that the
activation of EGFR signalling pathways was caused by the virus
debris, HNE1 cells were infected with EBV puriﬁed by high-speed
centrifugation in dextran T-10 density gradients for 1 h. EGFR,
AKT and ERK were phosphorylated by puriﬁed EBV (Fig. 6b),
indicating that the EGFR signalling pathway was indeed activated
by EBV. Knockdown of NRP1 partially suppressed the
phosphorylation of EGFR, AKT and ERK on EBV infection
(Fig. 6c), suggesting that NRP1 was associated with EBV
activation of EGFR/AKT and EGFR/ERK pathways.
To conﬁrm the role of RTK signalling pathways in EBV
infection, EGF-treated HNE1 and NPEC1-Bmi1 cells pre-
incubated with inhibitors of tyrosine kinases (Genistein),
MEK1/MEK2 (U0126), PI3K/AKT (LY294002), EGFR (Geﬁtinib)
and VEGFR2/PDGFR/Raf signalling cascades (Sorafenib), were
infected with EBV. Genistein, Geﬁtinib, Sorafenib and U0126
partially eliminated EBV entry, whereas LY294002 did not affect
EBV infection (Fig. 6d,e). These data suggested that the activation
of multiple RTKs and the downstream signalling Ras/Raf/MEK/
ERK rather than PI3K may enhance EBV infection.
As Genistein and Sorafenib partially impaired EBV infection,
we further investigated whether other signalling pathways besides
EGF/EGFR were also important for EBV infection. HNE1 cells
were transfected with siRNA duplexes targeting EGFR or c-Met
(receptor for HGF), followed by EBV infection. The expression
of EGFR and c-Met was nearly diminished in HNE1 cells
transfected with siEGFR or siMET. Knockdown of either EGFR
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or c-Met impaired EBV infection by about 50% (Fig. 6f,g),
indicating that there may be indeed other RTKs contributing to
EBV infection.
Furthermore, activated Ras (HRas V12) partially rescued the
suppressive effect of Geﬁtinib on EBV infection, conﬁrming that
HRas mediates EGFR-dependent EBV entry (Fig. 6h). Knock-
down of NRP1 even suppressed EBV infection in HNE1 cells with
persistently activated Ras (Fig. 6i), suggesting that the activated
Ras signalling was associated with but insufﬁcient for EBV
infection, and highlights the role of NRP1 in facilitating EBV
entry into nasopharyngeal epithelial cells.
Discussion
Epstein–Barr virus (EBV), an ubiquitous human herpesvirus, has
been classiﬁed as a group 1 carcinogen42,43. It is aetiologically
associated with lymphoid and epithelial tumours, suggesting its
primary tropism for these cells. The mechanism contributing to
EBV infection of B cells has been well documented, while the
mechanisms of cell-free EBV infection of epithelial cells remain
elusive. Here, we established a cell model relatively susceptible to
cell-free EBV infection, and highlighted the important role of
NRP1 in mediating cell-free EBV infection of nasopharyngeal
epithelial cell lines and EBV activated the RTK signalling
pathway.
In addition to cell-free EBV infection, cell-to-cell contact is
supposed to be an efﬁcient mode of EBV infection of diverse
human epithelial cells28. Like cell-free EBV infection, EGF
promotes the transmission of EBV from infected Akata cells to
uninfected HNE1 cells, partially depending on the expression of
NRP1 on the host cells (Supplementary Fig. 13), suggesting an
important role of NRP1 and EGF in facilitating not only cell-free
EBV infection, but also cell-to-cell contact-mediated infection.
EBV gB, the most highly conserved glycoprotein, is necessary
for EBV infection. It mainly presented as the trimeric form,
consistently with the previous report about the crystal analysis of
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EBV gB. EBV gB23–431, gB23–683 (the ectodomain of EBV-gB) and
gB23–853 (the almost full-length EBV-gB) showed interaction with
NRP1. In addition to the CendR motif, gB23–88 is another
important element contributing to the interaction between NRP1
and gB. Reimer et al.24 revealed that, although linker insertions at
position 88 did not affect cell-surface expression of gB, it
abrogated the ability of the variant protein to mediate fusion.
Backovic et al.23 reported residues 88 was a hydrophilic residue.
Therefore, gB23–88 may deﬁne novel binding sites for ligands,
such as a gB receptor or other EBV envelope glycoproteins
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involved in EBV infection23. We demonstrated that NRP1 and
NRP2 interacted with the glycoprotein gB, but had opposite effect
on EBV infection. Overexpression of NRP1 signiﬁcantly
promoted cell-cell fusion, while overexpression of NRP2 had no
effect on cell fusion. Both being as co-receptors for RTKs, NRP1
and NRP2 bind to different ligands. NRP1 binds to Sema3A and
initiates plexin signalling, which activates CRMP, ERK and Rac1,
whereas NRP2 binds to Sema3F and activates Rac GTPase-
activating protein (GAP) b2-Chimaerin30,44,45. Although the
exact mechanism underlying the discrepancy of NRP1 and NRP2
on the susceptibility of EBV infection remains to be determined,
it could be attributed to the different ligands they bind, and the
distinct downstream signalling pathways they activated. However,
we found that the ligands for NRP1 (SEMA3A, SEMA3F and
VEGF-A) had no effect on EBV infection, whether other ligands
for NRPs affect EBV infection of nasopharyngeal epithelial cells
remain further investigation.
It has been reported that the interaction between epithelial
integrins (for example, avb6, avb8 or a5b1) and EBV envelope
proteins (gHgL or BMRF2) is required for EBV infection of
epithelial cells originated from tongue, nasopharyngeal and
gastric carcinoma46,47. We found integrins av,b1 and b6, but
not integrins a5 and b8, may contribute to EBV infection of
nasopharyngeal epithelial cells (Supplementary Fig. 14).
Integrins bind the RGD/KGD motif-containing peptide, which
is cleaved by cell surface-associated proteases to expose the
cryptic CendR element, RXXK/R, at the C terminus. The CendR
element then mediates binding to NRP1, resulting in the
penetration of cells and tissues18. Both the full-length and
cleaved forms of gB are present in the puriﬁed EBV
(Supplementary Fig. 2). We therefore suppose the model that
EBV entry into epithelial cells: for the full-length gB-containing
EBV, EBV binds to nasopharyngeal epithelial cells through the
interaction between epithelial integrins (av, b1 and b6), or other
unknown factors and envelope proteins (gHgL or BMRF2). Then,
EBV gB was cleaved by furin to expose the CendR motif. For
cleaved gB containing EBV, the CendR motif may be already
exposed16,23. Followed by the interaction between the CendR
motif on the cleaved EBV gB and NRP1, EBV enters into
epithelial cells.
In addition to Geﬁtinib, Sorafenib and Genistein partially
impaired EBV infection, suggesting there are multiple RTKs and
the downstream signalling pathways other than EGFR contribut-
ing to EBV infection. This point was further conﬁrmed by the
evidence that knockdown of c-Met attenuated EBV infection.
Therefore, various RTKs signalling pathway may promote EBV
infection, and the detailed mechanisms are deserved to be further
investigated.
Multiple viruses, such as HTLV-1, possess CendR motifs
within their capsid proteins. Similarly, NRP1 also serves as an
entry factor for HTLV-1 through interaction with the KPXR
element (a CendR motif) exposed on its surface subunit (SU).
Whether NRP1-mediating RTK signalling pathways also play
important role in HTLV-1 infection remains to be further
investigated.
EBV gB is critical to mediate virus cell fusion48,49. We found
that NRP1 serves as an entry factor for EBV infection of
nasopharyngeal epithelial cells. However, whether NRP1 also
serves a similar function for EBV entry into B cells has not been
explored and deserves further investigation, although the
expression of NRP1 on B cells is quite low (Supplementary
Fig. 15). NRP1 not only functioned as an entry factor for EBV to
entry into epithelial cells, but was also associated with EBV-
activated EGFR/RAS/ERK signalling, which in turn potentiated
EBV infection (Fig. 7). As multiple inhibitors of receptor tyrosine
kinase signalling pathways impaired EBV infection, further
investigations are required both to investigate whether receptor
tyrosine kinases beyond EGFR are also involved in promoting
EBV infection, and to elucidate the detailed mechanism by which
NRP1 contributes to viral entry. Such ﬁndings would assist in the
development of anti-EBV agents that target this crucial stage in
virus infection.
Methods
Reagents. The reagents used were as follows: mouse monoclonal antibodies
against FLAG (F1804, Sigma-Aldrich, 1:2,000 dilution), a-tubulin (T6074,
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Sigma-Aldrich, 1:2,000 dilution), GAPDH (KC-5G4, Kangcheng Biotech., 1:3,000
dilution), GFP (sc-9996, Santa Cruz, 1:3,000 dilution) and EBV-gp350 (72A1, 1:200
dilution); rabbit monoclonal antibodies against NRP1 (2621-S, Epitomics Inc,
1:1,000 dilution), phospho-AKT1-Ser473 (#4060, Cell Signaling Technology, CST,
1:1,000 dilution), p-EGFR (Tyr1068, #3777, CST, 1:1,000 dilution), EGFR (#4267,
CST, 1:1,000 dilution), phospho-ERK1/2 (Thr202/Tyr204, #4376, CST, 1:1,000
dilution); rabbit polyclonal antibodies against AKT (KC-5A01, Kangcheng Bio-
tech., 1:1,000 dilution), ERK1/2 (KC-5E01, Kangcheng Biotech., 1:1,000 dilution);
sheep polyclonal antibody against NRP1 (AF3870, R&D Systems, 1:1,000 dilution);
goat polyclonal antibody against NRP2 (AF2215, R&D Systems, 1:500 dilution);
normal mouse/rabbit/goat IgG (R&D Systems). The horseradish peroxidase
(HRP)-conjugated goat-anti-mouse/rabbit secondary antibodies (Fisher Scientiﬁc,
1:3,000 dilution). HRP-conjugated donkey-anti-sheep secondary antibody (1:2,000
dilution) was gifted from R&D Systems. Alexa Fluor 594-conjugated goat-anti-
mouse (Molecular Probes, 1:2,000 dilution); 40-60-diamidino-2-phenylindole
(DAPI; Molecular Probes); soluble NRP1 (sNRP1, R&D Systems); EGF (E9644,
Sigma-Aldrich); BSA (A4737, Sigma-Aldrich). Geﬁtinib and Sorafenib were
purchased from SELLECK; U0126 and LY294002 were purchased from Merck;
Genistein, CPZ (Chlorpromazine), MbCD (Methyl-b-cyclodextrin) and EIPA
(5-(N-ethyl-N-isopropyl)-amiloride) were purchased from Sigma-Aldrich. All
other reagents were obtained from Sigma-Aldrich, unless otherwise indicated.
Cell culture. NPECs-Bmi1 cells and NP69 cells, grown in keratinocyte/serum-free
(KSF) medium (Invitrogen), were immortalized nasopharyngeal epithelial cells
induced by Bmi-1 or SV40T, respectively. All human EBV-negative NPC cell lines
(SUNE1, SUNE2, 6-10B, CNE1, CNE2 and HNE1) and EBV-positive cells (Akata
and Namalwa) maintained in our laboratory were cultured in RPMI 1640 medium
(GIBCO) supplemented with 5% fetal bovine serum (FBS, GIBCO). HEK-293FT
cells were cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM, Life
Technologies) supplemented with 10% FBS. Cells were grown in a humidiﬁed
5% CO2 incubator at 37 C and passaged using standard cell culture techniques.
Primary nasopharyngeal epithelial cells (NPEC03 and NPECw) were established
as followings: fresh biopsies of the nasopharynx, which were pathologically
exclusive of NPC, were collected from the Department of Head and Neck Surgery
at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. The specimen was cut
into pieces and plated onto T-25 culture ﬂask (Falcon) containing 2ml of KSF
medium. The cells grown out from the biopsies were propagated and stained with
anti-keratin (ZM-0069, Zhongshan Golden Bridge Biotechnology). This study was
approved by the Institute Research Ethics Committee at the Sun Yat-Sen Memorial
Hospital. Written informed consent was obtained from each patient.
Plasmids. To construct expression vectors for NRP1 and NRP2, the full-length
complementary DNA (cDNA) sequences of NRP1 and NRP2 were PCR-ampliﬁed
using cDNA from NPEC1-Bmi1 cells, and then integrated into the XhoI/EcoRI
sites in pMSCV-puro vector (Clontech) and into the HindIII/SalI sites in pLncx2-
neo vector (Clontech), named as pMSCV-NRP1 and pLncx2-NRP2, respectively.
To obtain the soluble form of the extracellular ABC domain of NRP1 or NRP2,
NRP130–862 ampliﬁed from pMSCV-NRP1 and NRP229-852 ampliﬁed from
pLncx2-NRP2 were inserted into pET32a vector (Merck) and pGEX-6p-1
vector (Invitrogen) to generate pET32a-NRP1ABC, pGEX-NRP1ABC and
pGEX-NRP2ABC, respectively.
To generate the expression vector (pCDNA3.1(þ )-NRP1) for soluble NRP1
used in an in vitro transcription–translation system, NRP130-636 was PCR-
ampliﬁed from pMSCV-NRP1, and then inserted into pCDNA3.1(þ ) vector
(Invitrogen).
To determine the fusion efﬁciency, plasmids pCAGT7 encoding T7 RNA
polymerase, and pT7EMCLuc carrying the ﬁreﬂy luciferase gene under the control
of the T7 promoter (gifted from Professor R. Longnecker, Northwestern
University) were used.
To investigate whether gB interacted with NRP1, the plasmids (pCEP-his-
FLAG-gB23–427, pCEP-his-FLAG-gB23–431, pCEP-his-FLAG-gB23–683, pCEP-his-
FLAG-gB89–431 and pCEP-his-FLAG-gB89–427) were constructed. The fragments
gB23–427, gB23–431, gB23–683, gB89–431 and gB89–427 were PCR-ampliﬁed from the
EBV glycoprotein gB expression plasmid p2670 (gifted from Professor W.
Hammerschmidt, Department of Gene Vectors, Helmholtz Zentrum Mu¨nchen)
and cloned into the pCEP-his vector.
To study the co-localization of EBV, NRP1 and the endocytosis markers,
ﬂuorescent protein-tagged NRP1 expression vectors (pEGFP-NRP1 and pMSCV-
NRP1-Mcherry) were generated. The cDNA sequence of NRP1 was PCR-ampliﬁed
from the vector pMSCV-NRP1, and then integrated into EcoRI/BamHI upstream
of the start codon of EGFP expression cassette in the pEGFP-N1 vector (Clontech),
under the control of CMV promoter, naming as pEGFP-NRP1, or inserted into
XhoI/EcoRI sites upstream of the start codon of Mcherry gene (ampliﬁed from
pCDNA-Mcherry gifted from Professor Jun Li, Sun Yat-Sen University) in a
modiﬁed pMSCV vector, under the control of PGK promoter, naming as pMSCV-
NRP1-Mcherry. The full-length cDNA sequence of SNX5 was PCR-ampliﬁed using
the cDNA from NPEC1-Bmi1 cells and cloned into the pEGFP-C2 vector
(Clontech), naming as pEGFP-SNX5. Plasmid EGFP-CLCa1 encoding EGFP-
tagged CLCa1 gene was gifted from Professor Yoshihiro Kawaoka (University of
Wisconsin-Madison). Plasmid pMSCV-HRAS-V12 for the activated Ras was gifted
from Professor Vimla Band (the University of Nebraska Medical Center). Primers
for cloning are listed in Supplementary Table 1.
siRNA oligoribonucleotides. ON-TARGET plus SMART pool siRNA duplexes
targeting ITGA5 (Cat# M-008003-02), ITGAV (Cat# M-004565-03), ITGB1 (Cat#
M-004506-00), ITGB6 (Cat# M-008012-01), ITGB8 (Cat# M-008014-02) and the
negative control siRNA (siControl, Cat# D-001220-01-20) duplex were purchased
from Dharmacon (Rockford). The negative control RNA duplex (siControl) for
siRNA was scrambled siRNA. The siRNA duplexes targeting two distinct sites of
human NRP1 mRNA (NCBI, NM_003873.5, Gene ID: 8829) were denoted as
siNRP1-1# and siNRP1-2#, while the siRNAs duplexes targeting two distinct sites
of human NRP2 mRNA (NCBI, NM_003872.2, Gene ID: 8828) were named as
siNRP2-1# and siNRP2-2#. The siRNA duplexes against NRP1 and NRP2 were
synthesized by GenePharma (Shanghai). All siRNA duplexes are listed in
Supplementary Table 2.
Cell transfection. Cell transfection was performed with Fugene HD (Roche),
Lipofectamine 2000 (Invitrogen) or Lipofectamine RNAiMAX (Invitrogen) as
indicated, according to the manufacturer’s instructions. For overexpression
experiments, HNE1 cells were plated at a density of 4–6 104 cells per well in
24-well plates. Sixteen hours after seeding, cells were grown to about 40%
conﬂuence, and each well received 1.5 ml Fugene HD and 0.75 mg of the indicated
plasmids. For immunoprecipitation assay, HEK-293FT cells were plated in six-well
plates at a density of 4 105 cells per well and grown to about 80% conﬂuence.
Sixteen hours after seeding, each well was co-transfected with 1 mg of pCEP-his-
FLAG-gB23-431 and 1 mg of pEGFP-NRP1 or pEGFP-NRP2 with 5 ml Lipofectamine
2000 for 36 h. For siRNA experiments, a ﬁnal concentration of 50 nM siRNA
duplex was reversely transfected with Lipofectamine RNAiMAX, unless otherwise
indicated.
Virus production. Akata cells carrying EBV, in which the thymidine kinase gene
was interrupted with a double cassette expressing GFP and neomycin resistance
gene, were resuspended in FBS-free RPMI 1640 medium at a concentration of
2–3 106 cells per ml, followed by induction with 0.75% (v/v) of goat anti-human
immunoglobulin G serum (Shuangliu Zhenglong Biochem.Lab) for 6 h at 37 C.
After culture in fresh RPMI1640 medium supplemented with 4% FBS for 3 days,
virus from the supernatant was collected under sterile conditions, passed through
two Millipore ﬁlters (0.8 and 0.45 mm), 100-fold concentrated by high-speed
centrifugation with 50,000 g, and then resuspended in fresh FBS-free RPMI1640
(ref. 50). The virus was stored at  80 C and thawed immediately before infection.
Cell-free EBV infection. EBV-negative NPEC/NPC cells were plated at a density
of 4–6 104 cells per well in 24-well plates and grown to about 60% conﬂuence.
Cells were brieﬂy washed with Hanks solution twice and were infected with 200 ml
EBV at a multiplicity of infection (MOI) of about 2.5 103 for 3 h at 37 C, unless
indicated. After brief wash with Hanks solution twice to remove unbound virus,
cells were cultured in the fresh medium for 48 h. The GFP-positive infected cells
were determined by ﬂuorescence microscopy (Olympus) and/or ﬂow cytometry
(Beckman Coulter FC500) at the indicated times post infection.
Determination of MOI. To determine the MOI (a multiplicity of infection) of
EBV, TaqMan real-time PCR was used to detect the BamHI-W fragment region of
the EBV genome51. A calibration curve was performed, using DNA extracted from
the EBV-positive cell line Namalwa, which contains two integrated viral genomes
per cell, as a standard.
To evaluate the infection efﬁciency of the newly puriﬁed EBV, 1 105 HNE1
cells plated in 24-well plate were infected with serial dilutions of EBV. The
percentage of infected cells was analysed by ﬂow cytometry 48 h post infection.
EBV infection increased along with the virus titres. About the MOI of 2 103 was
required for 20–30% of HNE1 cells to be infected, while an MOI of 1 104 was
required for 480% of HNE1 cells to be infected. Therefore, EBV infection of
epithelial cells was mediated in a virus titer-dependent manner.
Virus binding and internalization. Cells were seeded at the density of 5 104 cells
per well in 24-well plates for 24 h. To measure virus binding, cells were washed
with ice-cold Hanks solution twice and then were incubated with EBV for 3 h at
4 C to allow cell surface binding. The cells were then washed three times with ice-
cold Hanks solution to remove unbound virus. To measure virus internalization,
cells were washed with Hanks solution twice and then were incubated with EBV for
2 h at 37 C to allow internalization, then washed three times with Hanks solution
to remove unbound virus. To remove the surface-bound virus, the cell was
resuspended in 200 ml trypsin-EDTA (GIBCO) and proteinase K for 5min, and the
cell pellets were then washed three times with Hanks solution.
Cell fusion assay. HEK-293FT cells co-transfected with the expression vectors
(pCAGT7, p2670, pCAGGS-gH and pCAGGS-gL; expressing T7 polymerase, gB,
gH or gL, respectively) were used as effector cells. HEK-293FT cells
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co-transfected with pMSCV-NRP1 (or the empty vector pMSCV as control), a
reporter plasmid pT7EMCLuc encoding the luciferase gene driven by the T7
polymerase and an internal control plasmid pRL-SV40 encoding the Renilla luci-
ferase gene driven by the SV40 promoter served as target cells. Twenty-four hours
post transfection, the effector and target cells were detached using trypsin-EDTA
and co-cultured in a 24-well plate at a density of 2 105 for 24 h. Fireﬂy and
Renilla luciferase activities were assayed by using the dual-luciferase reporter assay
system (Promega) with the Veritas luminometer (Promega). The relative fusion
activity was calculated as the ratio of ﬁreﬂy luciferase activity to Renilla luciferase
activity. The mean value for pMSCV vector-transfected cells was normalized to
100% relative fusion activity.
Preparation of recombinant soluble NRPs protein. For blocking assays, soluble
NRP1ABC protein was prepared. The plasmid (pET32a-NRP1ABC), expressing the
soluble NRP1ABC, was transformed into E. coli strain BL21 (DE3). A single colony
was inoculated into 5ml LB-Amp (LB medium containing 100 mgml 1 ampicillin)
and grown at 37 C with vigorous shaking. The seed culture was then inoculated
into 500ml LB-Amp medium. When the OD600 reached 0.6–0.7, induction was
initiated by the addition of 50 mM isopropyl-1-thio-b-D-galactopyranoside (IPTG),
followed by a further 3 h shaking before collection. The culture was then cen-
trifuged, resuspended in 50ml cold NTA-buffer (50mM sodium phosphate at pH
8.0 and 0.3M NaCl) containing 1mM PMSF, and then sonicated on ice and
clariﬁed by centrifugation at 12,000 g for 10min. The 6His-FLAG-tagged
NRP1ABC protein in the precipitate was puriﬁed by Ni-NTA agarose (Fisher
Scientiﬁc). After elution with buffer (50mM sodium phosphate at pH 7.0, 300mM
NaCl, 6M urea and 150mM imidazole), soluble NRP1ABC protein was extensively
dialysed with RPMI1640, concentrated with Amicon Ultra-4 (Millipore) cen-
trifugation tubes with a 10-kDa molecular mass cutoff and was stored at  20 C.
To determine the afﬁnity constant, recombinant soluble GST-NRP1ABC and
GST-NRP2ABC proteins were prepared. The plasmid pGEX-GST-NRP1ABC or
pGEX-GST-NRP2ABC, expressing soluble GST-NRP1ABC or GST-NRP2ABC, was
transformed into E. coli strain Rosetta. A single colony was grown in the LB-Amp
medium. When the OD600 reached 0.6–0.7, induction was initiated by 200 mM
IPTG, followed by an overnight shaking at 18 C before collection. The culture was
centrifuged and homogenized with high pressure on ice and then centrifuged at
50,000 g for 120min. The GST-NRP1ABC and GST-NRP2ABC proteins were
puriﬁed by Glutathione agarose (Fisher Scientiﬁc). After elution with 10mM GSH
buffer (50mM Tris-HCl, pH 7.5, 150mM NaCl and 10mM GSH), the protein was
extensively dialysed with PBS buffer, and then stored at  20 C.
Determination of afﬁnity constant by ELISA. Microtiter plates were coated with
200 ng Flag-gB overnight at 4 C in a 96-well plate, followed by blocking with 5%
BSA in PBS for 2 h at RT, and then incubated with various concentrations of
GST-NRP1 and GST-NRP2 proteins for 2 h at RT. After washing with PBST
(0.05% Tween-20 in PBS), the plate was incubated with a Rabbit anti-GST antibody
(1:4,000 dilution) for 2 h at RT. The plate was then washed and incubated at 37 C
for 1 h with HRP-conjugated Goat anti-Rabbit antibody. After addition of the
substrate tetramethyl-benzidine, absorbance was measured at a wavelength of
450 nm using the Spectramax M5 (Molecular Devices).
Blocking assays. Blocking assays were performed with soluble NRP1ABC or
antibody against NRP2. To investigate whether soluble NRP1ABC would block EBV
infection, EBV pre-incubated with soluble NRP1ABC or BSA (as a negative control)
at 250 mgml 1 for 1 h, infected of HNE1 cells for 2 h at 37 C. To determine
whether antibody against NRP2 would promote EBV infection, HNE1 cells were
pre-incubated with 20mg anti-NRP2 antibody or goat IgG (as a negative control)
for 1 h and then were infected with EBV in the presence of an anti-NRP2 antibody
(100 mgml 1) for 3 h at 4 C. Cells were collected at 48 h post infection. The
percentages of GFP-positive infected cells were determined by a ﬂuorescence
microscope and/or ﬂow cytometry analysis.
Immunoprecipitation. The transfected cells were lysed in radio-
immunoprecipitation assay (RIPA) buffer (20mM Tris-HCl, pH 7.5, 150mM
NaCl, 2.5mM MgCl2, 5% glycerol and 0.5% Triton X-100) containing 1mM
phenylmethylsulfonyl ﬂuoride (PMSF) and Roche Complete protease inhibitor
cocktail (Roche Diagnostics Ltd, Mannheim, Germany). After centrifuged at
15,000 g for 20min at 4 C, the lysate was preincubated with protein G-Sepharose
beads (GE Healthcare) to preclear and then centrifuged at 15,000 g for 5min to
remove the beads. The supernatant was incubated with 2.5 mg (5 mgml 1) of the
indicated antibody at 4 C overnight, and the immune complexes were captured by
protein G-Sepharose beads for 2 h at 4 C. After washing three times in RIPA buffer
and twice in PBS to remove unbound proteins, the sample was suspended in
2 SDS-sample buffer and boiled for 5min. The complex proteins were then
analysed by western blotting, using speciﬁc detection antibodies.
Pull-down assay. Soluble NRP130-636 (sNRP130-636) was expressed by TnT Quick
Coupled Transcription/Translation Systems (promega), in the presence of canine
pancreatic microsomal membranes, according to the manufacturer’s instructions.
In brief, for each reaction, 1 mg of pCDNA3.1(þ )-sNRP1 and 1.5 ml canine
pancreatic microsomal membranes were incubated for 60min at 30 C.
HEK-293FT cells were plated in 10-cm2 dish at a density of 3–4 106 cells per
well and grown to 60–70% conﬂuency. After 16 h, each dish was transfected
with 20mg of pCEP-his-FLAG-gB23-431, pCEP-his-FLAG-gB24-427, pCEP-his-
FLAG-gB89-431 or pCEP-his-FLAG-gB89-427 with calcium phosphate transfection
for 36 h, followed by immunoprecipitation with anti-FLAG (M2) Sepharose beads
(Sigma). The M2-precipitated products were then incubated with sNRP130-636
overnight at 4 C. After washing three times in RIPA buffer to remove unbound
proteins, the sample was suspended in 2 SDS-sample buffer and then analysed by
western blotting.
EBV labelling with Alexa Fluor 594. Labelling of EBV was performed with Alexa
Fluro 594 (Aime-Reactive probes; MP) according to the manufacturer’s instruc-
tions and published procedures52,53. In brief, 20ml of 5mgml 1 Alexa Fluor 594
dissolved in dimethyl sulfoxide (DMSO) was mixed with 2ml of 200-fold
concentrated EBV in FBS-free RPMI1640 and 200ml of 0.5M carbonate-
bicarbonate buffer at pH 9.0 for 1 h in the dark at room temperature. To separate
the labelled EBV from the free dye, labelled EBV was diluted 10 times with cold
RPMI1640, centrifuged at 50,000 g for 90min at 4 C, and then resuspended in
1.5ml fresh FBS-free RPMI1640. The concentrated labelled virus was puriﬁed in
dextran T-10 gradients, followed by re-suspension in 2ml of fresh FBS-free
RPMI1640. The puriﬁed Alexa Fluro 594-labelled EBV was subsequently dialysed
four times with 500ml RPMI1640 per time, and then stored at  80 C until use.
Immunoﬂuorescence confocal microscopy. HNE1 cells were seeded on cover-
slips in 24-well plates at a density of 5 104 cells per well for 12–16 h, and then
transfected with the indicated plasmids for 24 h. Transfected cells infected with the
unlabelled EBV at an MOI of 5 103 for 1 h at 37 C were brieﬂy washed with PBS
twice, ﬁxed with 3% paraformaldehyde in PBS for 20min, and then permeabilized
with 0.1% Trtion X100 in PBS for 5min. After blocking with 5% BSA in PBS, EBV-
infected cells were stained with an antibody against gp350 (72A1, 1:200 dilution)
for 4 C overnight, and washed with PBST three times, followed by incubation with
Alexa Fluor 594-labelled goat antibody to mouse IgG (1:2,000 dilution). After wash
with PBST three times, cells were mounted with ProLong Gold mounting medium
(Invitrogen) containing 0.2 mgml 1 DAPI, which stains nuclei. Transfected cells
infected with Alexa Fluor 594-labelled EBV were washed, ﬁxed and then mounted
in mounting medium. The confocal images were acquired using a Leica TCS SP5
confocal laser scanning microscope.
Western blotting. Western blotting analysis was performed as previously
described54. In brief, cells were lysed in RIPA buffer containing a protease inhibitor
mixture (Roche) and incubated on a rocker at 4 C for 15min. The protein
concentration of the lysates were measured using the BCA protein assay kit
(Pierce) and were normalized to equal amounts of protein, separated by 9%
SDS/PAGE, transferred to PVDF and probed with the indicated primary
antibodies. After probed with the indicated antibodies, the blot was incubated with
species-speciﬁc HRP-conjugated secondary antibodies, and the immunoreactive
bands were visualized by enhanced chemiluminescence (ECL, Pierce). The same
membranes were then stripped and reprobed with mouse monoclonal antibodies
against GAPDH or a-tubulin to conﬁrm equal loading of the samples. Full scans of
all western blots are included in Supplementary Fig. 16–19.
RNA extraction, EBV DNA extraction and real-time PCR. Total cellular RNA
was extracted from cultured cells using the TRIzol reagent (Invitrogen) according
to the manufacturer’s instructions. cDNA was synthesized from 2 mg of the total
RNA using a reverse transcriptase kit (Invitrogen). The mRNA level was evaluated
by qRT–PCR using the Power SYBR Green qPCR SuperMix-UDG (Invitrogen) and
was analysed on Roche Lightcycler 480. All the gene expressions were normalized
to the housekeeping gene GAPDH, used as an internal standard. Primers are listed
in Supplementary Table 3. EBV DNA was extracted from EBV-infected cells using
Omega tissue DNA Mini Kit (Omega) as recommended by the manufacturer. The
copy number of EBV bound to the cell surface or internalized into HNE1 cells was
measured using TaqMan real time PCR for detection of the BamHI-W fragment
region of the EBV genome. Real-time PCR for the GAPDH DNA was used for cell
counting estimation. A calibration curve was performed with each analysis, using
DNA extracted from the EBV-positive cell line Namalwa, which contains two
integrated viral genomes per cell, as a standard. The EBV copy number was
expressed as a ratio of the copy number of the EBV genome to the copy number of
the GAPDH DNA.
Statistical analyses. The data are expressed as the mean±s.e.m. from at least
three independent experiments. Statistical analyses were performed with Graphpad
Prism 5 (GraphPad Software, San Diego, CA, USA).
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